| scholarly article | Q13442814 |
| P50 | author | Asfar S Azmi | Q37368661 |
| Yubin Ge | Q61731570 | ||
| P2093 | author name string | Min Liang | |
| Shuang Liu | |||
| Yang Xia | |||
| Guan Wang | |||
| Jeffrey W Taub | |||
| Holly Edwards | |||
| Ramzi M Mohammad | |||
| Gregory Dyson | |||
| Lijing Zhao | |||
| Lisa Polin | |||
| Changwen Ning | |||
| P2860 | cites work | Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression | Q27853310 |
| Phosphorylation and regulation of Raf by Akt (protein kinase B) | Q28138863 | ||
| Negative regulation of the serine/threonine kinase B-Raf by Akt | Q28139252 | ||
| Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis | Q28246808 | ||
| Random-effects models for longitudinal data | Q28279619 | ||
| Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia | Q28385690 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 | ||
| Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies | Q29616780 | ||
| The emerging mechanisms of isoform-specific PI3K signalling | Q29617954 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| PI3K and cancer: lessons, challenges and opportunities | Q30080017 | ||
| Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells | Q33831971 | ||
| Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer | Q34318452 | ||
| Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance | Q34466060 | ||
| Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells | Q34600369 | ||
| Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer | Q34808616 | ||
| Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. | Q35374899 | ||
| Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. | Q35848677 | ||
| Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Q37376388 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| Decoding and unlocking the BCL-2 dependency of cancer cells | Q38115674 | ||
| KRAS: feeding pancreatic cancer proliferation | Q38175666 | ||
| Targeting RAS-ERK signalling in cancer: promises and challenges | Q38272894 | ||
| Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities | Q38445723 | ||
| Improving Prospects for Targeting RAS. | Q38586951 | ||
| MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road | Q38591835 | ||
| Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. | Q38688079 | ||
| Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer | Q39023247 | ||
| Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 | ||
| In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 | ||
| GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. | Q40462682 | ||
| ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase | Q40744542 | ||
| PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. | Q46229463 | ||
| Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer | Q48087617 | ||
| Detection of mycoplasma contaminations. | Q54702212 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 44295-44311 | |
| P577 | publication date | 2017-05-15 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer | |
| P478 | volume | 8 |
| Q92845161 | Alkannin represses growth of pancreatic cancer cells based on the down regulation of miR-199a |
| Q43991475 | Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. |
| Q91997192 | Combination Therapy with a PI3K/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein-Barr Virus-Infected Gastric Cancer Cells |
| Q91811281 | Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells |
| Q57263190 | Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes |
| Q92978701 | Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics |
| Q91388651 | Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers |
| Q52310328 | PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT. |
| Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
| Q47281250 | Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. |
Search more.